Y Intercept Hong Kong Ltd Has $1.29 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Y Intercept Hong Kong Ltd decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 74.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 16,584 shares of the medical device company’s stock after selling 47,164 shares during the period. Y Intercept Hong Kong Ltd’s holdings in DexCom were worth $1,290,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Jennison Associates LLC lifted its stake in shares of DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the period. Congress Asset Management Co. increased its holdings in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD acquired a new position in DexCom in the fourth quarter valued at approximately $96,507,000. Westfield Capital Management Co. LP boosted its holdings in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after buying an additional 876,739 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after buying an additional 739,000 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Finally, Wells Fargo & Company raised their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average price target of $99.06.

DexCom Price Performance

DXCM opened at $89.91 on Thursday. The firm’s fifty day moving average price is $84.29 and its two-hundred day moving average price is $76.47. The company has a market capitalization of $35.13 billion, a price-to-earnings ratio of 62.87, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock worth $3,309,794 in the last 90 days. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.